RT Journal Article
SR Electronic
T1 Shoring Up Osteoporosis Management: A Fresh Start?
JF The Journal of the American Board of Family
                Medicine
JO J Am Board Fam Med
FD American Board of Family Medicine
SP 490
OP 493
DO 10.3122/jabfm.2024.240060R0
VO 37
IS 3
A1 Furr, Noah
A1 Ulmer, Ansley
A1 Cardon, Brock
A2 Mullen, Rebecca
YR 2024
UL http://www.jabfm.org/content/37/3/490.abstract
AB Anabolic bone agents, such as parathyroid hormone receptor agonists (teriparatide and abaloparatide) and sclerostin-inhibiting monoclonal antibody (romosozumab), are superior at preventing clinically significant fractures and/or vertebral fractures in women with and without severe osteoporosis compared with bisphosphonates.